Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insulet, DexCom team up for diabetes technology:

This article was originally published in Clinica

Executive Summary

Insulin pump manufacturer Insulet has combined with DexCom, a specialist in making glucose monitoring systems, in order to integrate the latter's technology into Insulet's handheld OmniPod system personal diabetes manager (PDM). The non-exclusive agreement sees San Diego, California-based DexCom provide Insulet with access to its continuous glucose monitoring technology, which when incorporated into the PDM, will allow diabetic patients to access real-time glucose values and receive alarms concerning high or low glucose levels. The two companies will develop the product over 2008, with product launch expected in mid-2009.

You may also be interested in...



AAM Slams Medicare Delays For First Generics

The AAM has cited multiple reasons for the failure of Medicare Part D to get new generics to its patients, forcing up their costs. The association has offered a list of suggestions to “ensure that first generics are covered at launch, with lower cost-sharing.”

FDA Recommends Further Limiting Use Of Laparoscopic Power Morcellation

The US FDA is updating its labeling guidance on laparoscopic power morcellation to reflect new evidence showing the treatment may pose a higher cancer risk in older women, as well as to add discussion of containment systems.

Generics Firms Deterred From Continuous Manufacturing

Rutgers University professor testifies in support of bill directing the FDA to designate National Centers of Excellence in Continuous Manufacturing; other bills target generic labeling, orphan exclusivity and counterfeit devices.

Topics

UsernamePublicRestriction

Register

MT045736

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel